Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Pre-market Movers » 09:02
01/06/22
01/06
09:02
01/06/22
09:02
VCRA

Vocera

$62.61 /

-3.95 (-5.93%)

, OBSV

ObsEva

$2.05 /

-0.09 (-4.22%)

, WBA

Walgreens Boots Alliance

$54.11 /

+0.63 (+1.18%)

, RGP

Resources Connection

$18.27 /

-0.1 (-0.54%)

, CAG

Conagra Brands

$34.13 /

-0.07 (-0.20%)

, BBBY

Bed Bath & Beyond

$13.37 /

-1.635 (-10.90%)

, BLI

Berkeley Lights

$16.26 /

-2.14 (-11.63%)

, SYK

Stryker

$272.35 /

-5.48 (-1.97%)

Check out this morning's…

ShowHide Related Items >><<
WBA Walgreens Boots Alliance
$54.11 /

+0.63 (+1.18%)

VCRA Vocera
$62.61 /

-3.95 (-5.93%)

SYK Stryker
$272.35 /

-5.48 (-1.97%)

RGP Resources Connection
$18.27 /

-0.1 (-0.54%)

OBSV ObsEva
$2.05 /

-0.09 (-4.22%)

CAG Conagra Brands
$34.13 /

-0.07 (-0.20%)

BLI Berkeley Lights
$16.26 /

-2.14 (-11.63%)

BBBY Bed Bath & Beyond
$13.37 /

-1.635 (-10.90%)

VCRA Vocera
$62.61 /

-3.95 (-5.93%)

12/20/21 Craig-Hallum
Vocera price target raised to $71 from $62 at Craig-Hallum
12/01/21 Jefferies
Vocera assumed with a Buy at Jefferies
11/29/21 Piper Sandler
Vocera price target raised to $68 from $61 at Piper Sandler
11/22/21 BTIG
Vocera price target raised to $70 from $60 at BTIG
OBSV ObsEva
$2.05 /

-0.09 (-4.22%)

11/29/21 H.C. Wainwright
ObsEva price target lowered to $15 from $17 at H.C. Wainwright
WBA Walgreens Boots Alliance
$54.11 /

+0.63 (+1.18%)

12/22/21 UBS
Walgreens Boots Alliance price target raised to $52 from $50 at UBS
12/22/21 Baird
Walgreens Boots Alliance price target raised to $70 from $68 at Baird
12/17/21 Morgan Stanley
Walgreens Boots Alliance downgraded to Underweight at Morgan Stanley
12/16/21 Morgan Stanley
Walgreens Boots Alliance downgraded to Underweight from Equal Weight at Morgan Stanley
RGP Resources Connection
$18.27 /

-0.1 (-0.54%)

01/06/22 Baird
Resources Connection price target raised to $21 from $19 at Baird
10/07/21 Baird
Resources Connection price target raised to $19 from $16
CAG Conagra Brands
$34.13 /

-0.07 (-0.20%)

10/08/21 JPMorgan
Conagra downgraded on limited earnings upside at JPMorgan
10/08/21 JPMorgan
Conagra Brands downgraded to Neutral from Overweight at JPMorgan
09/29/21
Fly Intel: Top five analyst upgrades
09/29/21 Credit Suisse
Conagra Brands upgraded to Neutral from Underperform at Credit Suisse
BBBY Bed Bath & Beyond
$13.37 /

-1.635 (-10.90%)

01/03/22 Wedbush
Bed Bath & Beyond price target lowered to $14 from $18 at Wedbush
11/03/21
Fly Intel: Top five analyst downgrades
11/03/21 Loop Capital
Loop Capital cuts Bed Bath & Beyond to Sell, cites deterioration in relevance
11/03/21 Loop Capital
Bed Bath & Beyond downgraded to Sell from Hold at Loop Capital
BLI Berkeley Lights
$16.26 /

-2.14 (-11.63%)

01/06/22 Stifel
Stifel downgrades Berkeley Lights, sees stock as 'dead money for a while'
01/06/22 William Blair
Berkeley Lights downgraded to Market Perform from Outperform at William Blair
01/06/22 BTIG
Berkeley Lights price target lowered to $25 from $45 at BTIG
01/06/22 Stifel
Berkeley Lights downgraded to Sell from Hold at Stifel
SYK Stryker
$272.35 /

-5.48 (-1.97%)

01/04/22 Piper Sandler
Zimmer Biomet downgraded to Neutral from Overweight at Piper Sandler
01/04/22 Piper Sandler
Stryker upgraded to Overweight from Neutral at Piper Sandler
12/15/21 Citi
Stryker price target lowered to $300 from $307 at Citi
12/09/21 RBC Capital
Stryker initiated with a Sector Perform at RBC Capital
WBA Walgreens Boots Alliance
$54.11 /

+0.63 (+1.18%)

VCRA Vocera
$62.61 /

-3.95 (-5.93%)

SYK Stryker
$272.35 /

-5.48 (-1.97%)

RGP Resources Connection
$18.27 /

-0.1 (-0.54%)

OBSV ObsEva
$2.05 /

-0.09 (-4.22%)

CAG Conagra Brands
$34.13 /

-0.07 (-0.20%)

BLI Berkeley Lights
$16.26 /

-2.14 (-11.63%)

BBBY Bed Bath & Beyond
$13.37 /

-1.635 (-10.90%)

WBA Walgreens Boots Alliance
$54.11 /

+0.63 (+1.18%)

BLI Berkeley Lights
$16.26 /

-2.14 (-11.63%)

BBBY Bed Bath & Beyond
$13.37 /

-1.635 (-10.90%)

WBA Walgreens Boots Alliance
$54.11 /

+0.63 (+1.18%)

VCRA Vocera
$62.61 /

-3.95 (-5.93%)

SYK Stryker
$272.35 /

-5.48 (-1.97%)

RGP Resources Connection
$18.27 /

-0.1 (-0.54%)

CAG Conagra Brands
$34.13 /

-0.07 (-0.20%)

BLI Berkeley Lights
$16.26 /

-2.14 (-11.63%)

BBBY Bed Bath & Beyond
$13.37 /

-1.635 (-10.90%)

WBA Walgreens Boots Alliance
$54.11 /

+0.63 (+1.18%)

RGP Resources Connection
$18.27 /

-0.1 (-0.54%)

BBBY Bed Bath & Beyond
$13.37 /

-1.635 (-10.90%)

Hot Stocks
ObsEva announces results from Phase 3 EDELWEISS 3 trial of linzagolix » 07:14
01/06/22
01/06
07:14
01/06/22
07:14
OBSV

ObsEva

$2.05 /

-0.09 (-4.22%)

ObsEva SA announced…

ObsEva SA announced "positive" topline results from the Phase 3 EDELWEISS 3 trial of linzagolix, an oral GnRH antagonist, in women with moderate-to-severe endometriosis-associated pain, EAP. Two doses were tested, a 200 mg once-daily dose of linzagolix in combination with add-back therapy, ABT, and a 75 mg dose of linzagolix without ABT. The 200 mg dose met the co-primary efficacy objectives, demonstrating reductions in dysmenorrhea, DYS, and non-menstrual pelvic pain, NMPP, at 3 months. There were statistically significant and clinically meaningful improvements in the first five ranked secondary endpoints at 6 months: dysmenorrhea, non-menstrual pelvic pain, dyschezia, overall pelvic pain, and ability to do daily activities. The 75 mg dose without ABT demonstrated a statistically significant reduction versus placebo in DYS at 3 months. Although it showed improvement in NMPP at 3 months, it did not reach statistical significance versus placebo, and thus did not meet the co-primary efficacy objective. Improvements were also observed at 6 months in the first five ranked secondary endpoints, as for the 200 mg plus ABT dose. Both linzagolix doses were generally well-tolerated with minimal BMD decrease and few adverse events occurring in more than 5% of patients up to 6 months.

ShowHide Related Items >><<
OBSV ObsEva
$2.05 /

-0.09 (-4.22%)

OBSV ObsEva
$2.05 /

-0.09 (-4.22%)

11/29/21 H.C. Wainwright
ObsEva price target lowered to $15 from $17 at H.C. Wainwright
OBSV ObsEva
$2.05 /

-0.09 (-4.22%)

Hot Stocks
Aspira Women's Health announces fourth quarter operational metrics, updates » 08:26
01/05/22
01/05
08:26
01/05/22
08:26
AWH

Aspira Women's Health

$1.72 /

-0.09 (-4.99%)

, OBSV

ObsEva

$2.14 /

-0.035 (-1.61%)

, ABBV

AbbVie

$135.14 /

-0.27 (-0.20%)

Aspira Women's…

Aspira Women's Health (AWH) announced preliminary fourth quarter operational results and provided a corporate update. Operational Metrics Update: OVA1 volume in the fourth quarter of 2021 grew approximately 23.4% year over year to 4,750 units compared to 3,849 units in the fourth quarter of 2020. The number of tests for the fourth quarter represented a quarterly record and a 11% increase sequentially compared to the third quarter test volume of 4,281. The number of ordering physicians increased to approximately 3,211 for the fourth quarter of 2021, representing a year over year increase of 22.8% and a sequential increase of 10.2% for the quarter. The number of new physician additions increased 31% from third quarter of 2021 vs fourth quarter of 2021. Pipeline Update: OvaWatch: The company plans to launch our laboratory developed test OvaWatch in two stages - single use and serial monitoring. For the single use test, the company submitted the analytical validation manuscript in late November. It plans to launch the single use test following acceptance of both manuscripts. Launch of the serial monitoring test is currently planned for the end of 2022/early 2023. EndoCheck: Aspira is developing an LDT with the specimens provided by collaborators, ObsEva (OBSV) and AbbVie (ABBV), while simultaneously seeking FDA Breakthrough Designation for EndoCheck with the first FDA "Principles for Good Machine Learning Practices." Aspira also plans to hold a key opinion leader event in the first quarter of 2022 with top thought leaders in the field to discuss the disease, the clinical gaps, the regulatory opportunity with LDT's, and our science.

ShowHide Related Items >><<
OBSV ObsEva
$2.14 /

-0.035 (-1.61%)

AWH Aspira Women's Health
$1.72 /

-0.09 (-4.99%)

ABBV AbbVie
$135.14 /

-0.27 (-0.20%)

AWH Aspira Women's Health
$1.72 /

-0.09 (-4.99%)

03/29/21 Truist
Aspira Women's Health initiated with a Buy at Truist
03/29/21 Truist
Aspira Women's Health initiated with a Buy at Truist
01/28/21 Cantor Fitzgerald
Cantor Fitzgerald starts Aspira Women's Health at Overweight with $10 target
01/28/21 Cantor Fitzgerald
Aspira Women's Health initiated with an Overweight at Cantor Fitzgerald
OBSV ObsEva
$2.14 /

-0.035 (-1.61%)

11/29/21 H.C. Wainwright
ObsEva price target lowered to $15 from $17 at H.C. Wainwright
ABBV AbbVie
$135.14 /

-0.27 (-0.20%)

01/05/22 Mizuho
Mizuho keeps AbbVie as top 2022 large cap pick, ups target
01/03/22 Piper Sandler
AbbVie price target raised to $160 from $129 at Piper Sandler
12/17/21 Goldman Sachs
AbbVie initiated with a Neutral at Goldman Sachs
12/08/21 Wells Fargo
Vertex Pharmaceuticals initiated with an Overweight at Wells Fargo
OBSV ObsEva
$2.14 /

-0.035 (-1.61%)

AWH Aspira Women's Health
$1.72 /

-0.09 (-4.99%)

ABBV AbbVie
$135.14 /

-0.27 (-0.20%)

  • 04
    Feb
ABBV AbbVie
$135.14 /

-0.27 (-0.20%)

ABBV AbbVie
$135.14 /

-0.27 (-0.20%)

ABBV AbbVie
$135.14 /

-0.27 (-0.20%)

Over a month ago
Hot Stocks
ObsEva added to the Nasdaq Biotechnology Index » 07:04
12/20/21
12/20
07:04
12/20/21
07:04
OBSV

ObsEva

$2.24 /

+0.075 (+3.47%)

, NBI

Nasdaq Biotechnology Index

/

+

ObsEva announced it has…

ObsEva announced it has been selected for addition to the NASDAQ Biotechnology Index, effective as of market open on Monday, December 20, 2021.

ShowHide Related Items >><<
OBSV ObsEva
$2.24 /

+0.075 (+3.47%)

NBI Nasdaq Biotechnology Index
/

+

OBSV ObsEva
$2.24 /

+0.075 (+3.47%)

11/29/21 H.C. Wainwright
ObsEva price target lowered to $15 from $17 at H.C. Wainwright
01/04/21 H.C. Wainwright
ObsEva price target lowered to $17 from $23 at H.C. Wainwright
NBI Nasdaq Biotechnology Index
/

+

OBSV ObsEva
$2.24 /

+0.075 (+3.47%)

Hot Stocks
ObsEva announces positive CHMP opinion for linzagolix » 07:10
12/17/21
12/17
07:10
12/17/21
07:10
OBSV

ObsEva

$2.18 /

-0.06 (-2.68%)

ObsEva announced that the…

ObsEva announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, adopted a positive opinion recommending approval of linzagolix, an oral GnRH antagonist for the management of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. ObsEva's Marketing Authorisation Application submission was based on positive data from the Company's two Phase 3 PRIMROSE trials. "The positive CHMP opinion is an important milestone for millions of women in the EU living with UF to address the diverse medical needs of the women who suffer from this condition," said Brian O'Callaghan, CEO of ObsEva. "We will continue our productive, ongoing dialogue with EMA toward potential marketing authorization in the EU, and in parallel, continue to work with the FDA to advance linzagolix through the U.S. regulatory process." The positive opinion adopted by the CHMP is based on 52-week treatment results from the Phase 3 PRIMROSE 1 and PRIMROSE 2 clinical studies as well as supportive results from the 76-week post-treatment follow-up periods of both trials. A final marketing authorization decision from the EC is anticipated within two months.

ShowHide Related Items >><<
OBSV ObsEva
$2.18 /

-0.06 (-2.68%)

OBSV ObsEva
$2.18 /

-0.06 (-2.68%)

11/29/21 H.C. Wainwright
ObsEva price target lowered to $15 from $17 at H.C. Wainwright
01/04/21 H.C. Wainwright
ObsEva price target lowered to $17 from $23 at H.C. Wainwright
OBSV ObsEva
$2.18 /

-0.06 (-2.68%)

Recommendations
ObsEva price target lowered to $15 from $17 at H.C. Wainwright » 06:17
11/29/21
11/29
06:17
11/29/21
06:17
OBSV

ObsEva

$2.25 /

+0.02 (+0.90%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on ObsEva to $15 from $17 and keeps a Buy rating on the shares post the Q3 results.

ShowHide Related Items >><<
OBSV ObsEva
$2.25 /

+0.02 (+0.90%)

OBSV ObsEva
$2.25 /

+0.02 (+0.90%)

01/04/21 H.C. Wainwright
ObsEva price target lowered to $17 from $23 at H.C. Wainwright
OBSV ObsEva
$2.25 /

+0.02 (+0.90%)

Hot Stocks
ObsEva announces FDA acceptance of linzagolix NDA » 05:32
11/22/21
11/22
05:32
11/22/21
05:32
OBSV

ObsEva

$2.32 /

+0.11 (+4.98%)

Obseva announced that the…

Obseva announced that the new drug application, or NDA, for linzagolix for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women has been accepted for review by the FDA. The submission is based on data from the two Phase 3 PRIMROSE trials. Linzagolix has a differentiated profile and if approved, would be the first and only GnRH receptor antagonist with flexible dosing options for uterine fibroids, including a low dose option to address the needs of women who cannot or do not want to take hormones. The FDA set a target action date of September 13, 2022 for this NDA under the Prescription Drug User Fee Act.

ShowHide Related Items >><<
OBSV ObsEva
$2.32 /

+0.11 (+4.98%)

OBSV ObsEva
$2.32 /

+0.11 (+4.98%)

01/04/21 H.C. Wainwright
ObsEva price target lowered to $17 from $23 at H.C. Wainwright
OBSV ObsEva
$2.32 /

+0.11 (+4.98%)

Hot Stocks
Bolt Biotherapeutics appoints Brian O'Callaghan, Frank Lee to board » 08:14
11/19/21
11/19
08:14
11/19/21
08:14
BOLT

Bolt Biotherapeutics

$8.82 /

-0.17 (-1.89%)

, OBSV

ObsEva

$2.21 /

-0.12 (-5.15%)

, FMTX

Forma Therapeutics

$17.95 /

-0.595 (-3.21%)

Bolt Biotherapeutics…

Bolt Biotherapeutics (BOLT) announced the appointments of Brian O'Callaghan and Frank Lee to the Board of Directors. With these additions, longtime Director Peter Moldt, Ph.D. is stepping down from the Board of Directors and current Director Jim Healy, M.D., Ph.D. will be assuming the role of Lead Independent Director. O'Callaghan currently serves as Chief Executive Officer at ObsEva SA (OBSV), a clinical-stage pharmaceutical company developing novel therapies to improve women's health. Lee currently serves as President and Chief Executive Officer of Forma Therapeutics (FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers.

ShowHide Related Items >><<
OBSV ObsEva
$2.21 /

-0.12 (-5.15%)

FMTX Forma Therapeutics
$17.95 /

-0.595 (-3.21%)

BOLT Bolt Biotherapeutics
$8.82 /

-0.17 (-1.89%)

BOLT Bolt Biotherapeutics
$8.82 /

-0.17 (-1.89%)

03/02/21
Fly Intel: Top five analyst initiations
03/02/21 SVB Leerink
Bolt Biotherapeutics initiated with an Outperform at SVB Leerink
03/02/21 Morgan Stanley
Bolt Biotherapeutics initiated with an Overweight at Morgan Stanley
03/02/21 Stifel
Bolt Biotherapeutics initiated with a Buy at Stifel
OBSV ObsEva
$2.21 /

-0.12 (-5.15%)

01/04/21 H.C. Wainwright
ObsEva price target lowered to $17 from $23 at H.C. Wainwright
FMTX Forma Therapeutics
$17.95 /

-0.595 (-3.21%)

10/07/21 Oppenheimer
Forma Therapeutics' FT-7051 'high encouraging', says Oppenheimer
08/17/21 H.C. Wainwright
Forma Therapeutics price target lowered to $53 from $55 at H.C. Wainwright
08/02/21
Fly Intel: Top five analyst initiations
08/02/21 Craig-Hallum
Forma Therapeutics initiated with a Buy at Craig-Hallum
OBSV ObsEva
$2.21 /

-0.12 (-5.15%)

FMTX Forma Therapeutics
$17.95 /

-0.595 (-3.21%)

BOLT Bolt Biotherapeutics
$8.82 /

-0.17 (-1.89%)

  • 05
    Feb
  • 11
    Dec
BOLT Bolt Biotherapeutics
$8.82 /

-0.17 (-1.89%)

Syndicate
ObsEva files to sell 11.5M shares of common stock for holders  17:25
11/10/21
11/10
17:25
11/10/21
17:25
OBSV

ObsEva

$2.41 /

-0.06 (-2.43%)

 
ShowHide Related Items >><<
OBSV ObsEva
$2.41 /

-0.06 (-2.43%)

OBSV ObsEva
$2.41 /

-0.06 (-2.43%)

01/04/21 H.C. Wainwright
ObsEva price target lowered to $17 from $23 at H.C. Wainwright
OBSV ObsEva
$2.41 /

-0.06 (-2.43%)

Hot Stocks
ObsEva announces departure of CFO David Renas » 16:31
10/29/21
10/29
16:31
10/29/21
16:31
OBSV

ObsEva

$2.59 /

+0.015 (+0.58%)

ObsEva SA announced that…

ObsEva SA announced that current Chief Financial Officer David Renas will be stepping down from his position for personal reasons, effective January 5, 2022. ObsEva has retained an executive search firm to assist the company's board with identifying a new Chief Financial Officer.

ShowHide Related Items >><<
OBSV ObsEva
$2.59 /

+0.015 (+0.58%)

OBSV ObsEva
$2.59 /

+0.015 (+0.58%)

01/04/21 H.C. Wainwright
ObsEva price target lowered to $17 from $23 at H.C. Wainwright
11/09/20 JPMorgan
ObsEva downgraded to Underweight from Neutral at JPMorgan
OBSV ObsEva
$2.59 /

+0.015 (+0.58%)

  • 30
    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.